Phase III Data, FDA Interactions Bode Well For Portola’s Factor Xa Antidote
This article was originally published in The Pink Sheet Daily
Executive Summary
Breakthrough drug andexanet alfa meets all endpoints for reversing effects of Bristol/Pfizer’s Eliquis in Phase III, bringing the company a step closer to a filing for an accelerated approval by year’s end.